Latest Articles

Publication Date
Post-marketing safety profile of Myfembree in approved gynecologic indications: a disproportionality analysis based on the FAERS database.

Myfembree, a fixed-dose combination of relugolix, estradiol, and norethindrone acetate, is approved for premenopausal women with heavy menstrual bleeding associated with uterine fibroids and moderate to severe pain associated with …

Published: Sept. 24, 2026, midnight
Self-Reported Experiences of Women Taking Hormonal Treatments for Their Endometriosis and Uterine Fibroids Symptoms: Results from a Real-World Study in the US (MyEndoUF).

To characterize the experiences of individuals taking hormonal therapies to manage their symptoms of endometriosis (EM) or uterine fibroids (UF).

Published: Sept. 17, 2026, midnight
Association Between Endometriosis and Autoimmune Thyroid Disease Using a Multicenter Observational Medical Outcomes Partnership (OMOP) Common Data Model.

Background: Endometriosis affects approximately 6-10% of women of reproductive age-an estimate that varies substantially with the diagnostic standard applied-and is increasingly recognized as a systemic inflammatory disease. Growing evidence implicates …

Published: Sept. 7, 2026, midnight
Real-world effectiveness and tolerability of dienogest in patients with endometriosis: a cross-sectional patient-reported-study.

To evaluate the effectiveness and tolerability of dienogest in patients with endometriosis in real-world clinical practice.

Published: Sept. 3, 2026, midnight
Consumer-driven approach to determining health research priorities: what matters most to people living in rural Australia?

Rural, regional and remote (henceforth 'rural') communities face unique health challenges, including limited access to health care, workforce shortages, and higher disease burden. Consumer and community involvement is essential for …

Published: Sept. 1, 2026, midnight
A transcriptomics-based computational drug repurposing pipeline identifies simvastatin and primaquine as therapeutics for endometriosis.

Endometriosis has limited treatment options, prompting the search for data-driven therapeutics. We previously used a transcriptomics-based computational drug repositioning pipeline and identified several drug candidates. Fenoprofen, our top in silico …

Published: Aug. 21, 2026, midnight
Endometriosis-Associated Infertility in China: Epidemiological Trends, Future Projection, and Real-World Clinical Insights.

Endometriosis-associated infertility (EAI) has emerged as an increasingly pressing reproductive health problem. Nevertheless, existing epidemiological research on EAI remains inadequate.

Published: Aug. 18, 2026, midnight
The Role of Artificial Intelligence in the Radiological Diagnosis of Urogynecological and Obstetric Disorders: A Narrative Review.

Artificial intelligence (AI) has emerged as a transformative tool in radiological diagnosis, particularly in urogynaecology and obstetric disorders where accurate and timely imaging is essential. This narrative review evaluates current …

Published: Aug. 18, 2026, midnight
Real-word evidence on the effectiveness of the Endo-App in reducing endometriosis-related complaints: a retrospective analysis.

Randomized controlled clinical trials have shown that symptoms of chronic pain conditions, such as endometriosis, can be improved with the use of specialized health apps. In the current study, real-world …

Published: July 27, 2026, midnight
Comparative effectiveness of hormonal therapies for preventing recurrence in endometriosis: a real-world retrospective cohort study with risk factor analysis.

Endometriosis is a common chronic disease in women of reproductive age, and long-term postoperative medical management is a key strategy for preventing recurrence. Currently used clinical medications include dienogest (DNG), …

Published: June 30, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!